Unlocking Opportunities in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Key Growth Trends and Forecast Insights
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Growth Potential of the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, and How Will It Perform by 2034?
There has been substantial growth in the market size for the treatment of Chronic Obstructive Pulmonary Disease (COPD) in recent years. The market, valued at $20.84 billion in 2024, is expected to increase to $21.94 billion in 2025, with a compound annual growth rate (CAGR) of 5.3%. Various factors can be associated with this historic growth including a rising smoking and tobacco usage, advancements in inhalation therapies, early detection through awareness campaigns, government interventions for respiratory wellbeing, and ongoing research and development in pulmonology.
The market size for the treatment of chronic obstructive pulmonary disease (COPD) is anticipated to witness robust growth in the coming years, scaling up to “$27.74 billion by 2029 with a compound annual growth rate (CAGR) of 6.0%. This anticipated growth during the forecast period is linked to factors such as personalized medicine and biomarker research, biologic therapies, targeted interventions, concerns about air quality and environmental factors, worldwide initiatives for smoking cessation, and partnerships for drug development. The future landscape of the COPD treatment market will also see emerging trends such as digital health solutions for managing COPD, developing biologic therapies, the rise of personalized medicine, combination therapy methods and inhalers, earlier diagnoses with interventions and pulmonary rehabilitation programs.
What Industry-Specific Factors Are Fueling the Growth of the chronic obstructive pulmonary disease (copd) treatment Market?
The growth of the chronic obstructive pulmonary disease (COPD) treatment market is likely to be fueled by the surging prevalence of lung disease. Lung disease refers to any condition that impedes the lungs’ normal functioning. Among the most prevalent lung diseases are asthma, COPD, and lung cancer. The primary function of Chronic Obstructive Pulmonary Disease (COPD) treatment is to manage lung disease, slow its progression, control the symptoms, and prevent further lung damage using inhalers and medications. For example, the Global Initiative for Chronic Obstructive Lung Disease (GOLD), a US-based non-profit organization, stated that as of September 2022, 3.2 million people die from COPD annually, affecting an estimated 200 million people globally. Furthermore, in 2022, asthma affected 262 million people worldwide and these figures are projected to grow in the future. Additionally, as the LUNGevity Foundation, a US-based non-profit organization, predicted in 2023, lung cancer will cause 127,000 deaths in the US every year. Consequently, the escalating prevalence of lung diseases is contributing to the expansion of the chronic obstructive pulmonary disease (COPD) treatment market.
Request Your Free Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10054&type=smp
Who Are the Major Companies Shaping the Competitive Landscape of the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market include:
• Almirall S.A._x000D_
• AstraZeneca plc_x000D_
• Boehringer Ingelheim International GmbH_x000D_
• F. Hoffmann-La Roche Ltd._x000D_
• GlaxoSmithKline plc_x000D_
What Are the Key Emerging Trends in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market for the Next Decade?
In the Chronic Obstructive Pulmonary Disease (COPD) treatment market, one of the most notable trends is the emphasis on product innovation. Major players in this market are creating innovative treatments to maintain a strong market presence. Take for instance GlaxoSmithKline plc (GSK), a UK-based pharma and biotech firm, which in April 2022, introduced Trelegy Ellipta, a first of its kind single-inhaler triple treatment (SITT) for COPD patients in India. This product, made for the treatment and prevention of COPD symptoms in individuals aged 18 and over, functions in a manner similar to natural corticosteroid hormones. It works by attaching itself to specific immune cell receptors and lessening their activity. It also aids in alleviating lung airway inflammation, making it easier for patients to breathe.
Pre-order Your Report for Quick and Easy Delivery!
Which Key Market Segments Comprise the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market and Drive Its Revenue Growth?
The chronic obstructive pulmonary disease (COPD) treatment market covered in this report is segmented –
1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS), Long-Acting Muscarinic Antagonists (LAMA) + LABA, Triple Therapy (LAMA + LABA + ICS)
2) By Bronchodilators: Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA)
3) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Injectable Corticosteroids
4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast, Other PDE4 Inhibitors
5) By Mucokinetics: Expectorants, Mucolytics
6) By Other Drug Classes: Antibiotics, Antivirals, Antifungal Agents
Which Regions Are Making a Mark in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth?
North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2024.Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (COPD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
How Is the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Categorized and Defined in the Industry?
Chronic obstructive pulmonary disease (COPD) treatment refers to medical care given to a patient that helps manage the symptoms, slow the progression, and improve the overall quality of life of individuals with COPD. COPD is a progressive respiratory disease characterized by airflow obstruction, chronic inflammation, and damage to the lung tissue.
Browse Through More Similar Reports By The Business Research Company:
Endoscopy Devices And Equipment Global Market Report 2024
Gastrointestinal Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/gastrointestinal-devices-global-market-report
Dialysis Devices And Equipment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: